NCT04140773

The Effect of D-serine as add-on Therapy in Recent-onset Psychosis

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Dragos Inta · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms. However, it is important that negative symptoms and cognitive impairment are treated as well, as they both play a large part in the acute episode and long-term course of schizophrenia outcome. Previous studies have used D-serine as add-on treatment in patients with psy-chotic disorders and high-risk patients, with positive results. So far, no study has investigated the effects in a sample of recent-onset psychosis patients. Therefore, this study will include 30 patients (18-50 years old) with recent-onset psychosis. In addition to their regular treatment, patients will receive either D-serine (2 g/d) or placebo for 6 weeks. D-serine is an amino-acid naturally occurring in the brain which is prescription-free available as nutritional supplement. The primary outcome measure is total score on the Positive and Negative Syndrome Scale (PANSS). Secondary measure-ments include PANSS subscales, neurocognitive tests, (f)MRI, and EEG

Conditions

• Psychotic Disorder

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	D-serine	Capsule D-serine
OTHER	Placebo	Capsule D-serine

Timeline

• Start date: 2021-11-25
• Primary completion: 2022-08-31
• Completion: 2022-08-31
• First posted: 2019-10-28
• Last updated: 2022-09-10

Locations

1 site across 1 country: Switzerland